Adaptimmune Therapeutics plc
60 Jubilee Avenue
Milton Park
Abingdon OX14 4RX
United Kingdom
44 12 3543 0000
https://www.adaptimmune.com
版塊: Healthcare
行業: Biotechnology
全職員工: 449
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Adrian G. Rawcliffe | CEO, Principal Accounting Officer & Director | 1.06M | 199.16k | 1972 |
| Dr. Helen Katrina Tayton-Martin MBA, Ph.D. | Co-Founder & Chief Business & Strategy Officer | 677.4k | 無 | 1967 |
| Mr. Gavin Hilary James Wood ACA, BA (Hons) | Chief Financial Officer | 666.34k | 無 | 1970 |
| Mr. William C. Bertrand Jr., Esq., J.D. | Chief Operating Officer | 707.34k | 76.95k | 1965 |
| Dr. Elliot Norry B.A., M.D. | Chief Medical Officer | 676.19k | 65.02k | 1964 |
| Ms. Joanna Brewer Ph.D. | Chief Scientific Officer | 無 | 無 | 1976 |
| Dr. Juli P. Miller Ph.D. | VP of Corporate Affairs & Investor Relations | 無 | 無 | 無 |
| Ms. Kerry Sharp | Senior VP & General Council | 無 | 無 | 無 |
| Dana Lynch | Senior Director of Corporate Communications | 無 | 無 | 無 |
| Mr. John Lunger | Chief Patient Supply Officer | 645.91k | 148.2k | 1970 |
描述
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
公司管治
截至 無 止，Adaptimmune Therapeutics plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
